Project Details
Description
ABSTRACT
Vaccine-based prevention of breast cancer is a promising strategy for substantially reducing the impact of
disease incidence, treatment, and mortality because vaccines can induce highly specific immune responses that
self-regulate in the absence of disease. Ongoing clinical trials of vaccines targeting antigens expressed by breast
cancer cells, including ongoing trials from members of this research group, have shown that vaccines can induce
T-cell-based immunity that can last for years. Effective implementation of a prevention vaccine will require
identification of which antigens are associated with breast cancer risk and progression and definition of tissue-
and blood-based metrics of vaccine response. The experiments presented in this project will pair with our new
Phase Ib trial of a novel multi-antigen prevention vaccine to advance it toward a clinical prevention trial. In our
first Specific Aim, we will draw upon an extensive tissue resource of women diagnosed with benign breast
disease at the Mayo Clinic and at the Karmanos Cancer Center to assess which of the antigens in the prevention
vaccine are expressed in premalignant breast tissue and which are most associated with subsequent breast
cancer development. This information will be critical for identifying which antigens should be included in the
future prevention trial and which patients are most likely to benefit from it. In our second Specific Aim, we will
evaluate blood-based antibody and cellular immune responses to the multiantigen vaccine in our current Phase
1b clinical trial. We will use high dimensional cellular analysis and targeted sequencing approaches, information
that will provide minimally invasive endpoints of immune response for a larger scale future prevention trial. In
our third Specific Aim, we will assess pre- and post-vaccine background normal breast tissues from patients in
the clinical trial to identify how changes in antigen expression are associated with activation of specific immune
cell subtypes and changes in the T- and B-cell repertoire. This information will inform the future prevention trial
by defining how the vaccine and its specific components impact antigen expression and immune response in
nonmalignant breast tissue. Successful completion of this project will define which vaccine components should
be advanced to a larger vaccine-based breast cancer prevention clinical trial, which has the potential to drive
significant reductions in overall disease incidence, burden and mortality.
Status | Finished |
---|---|
Effective start/end date | 9/21/22 → 8/31/23 |
Funding
- National Cancer Institute: $490,073.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.